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Antibiotic resistance 
pre-dates penicillin
Clinical antimicrobial resistance 
was first reported four years 
before Alexander Fleming’s 
discovery of penicillin in 1928. 
The antimicrobial in question was 
known as Salvarsan (S. Silberstein 
Arch. Derm. Syph. 147, 116–130; 
1924).
An antibiotic was originally 
defined as an agent that 
microorganisms produce 
to kill competing bacteria 
(S. A. Waksman Mycologia 39, 
565–569; 1947). This has been 
extended to include synthetic 
drugs, including sulfonamides 
and quinolones. Salvarsan 
was one such drug, from a 
group of compounds known as 
arsphenamines. It was used to 
treat syphilis from 1910 until 
the 1940s, when penicillin took 
over because it was more readily 
available, safer and more effective. 
Bacterial resistance to 
Salvarsan started to emerge about 
halfway through that period, 
despite the drug’s limited use 
by comparison with modern 
antibiotics. The 1924 paper was 
cited by several groups during the 
1930s (see, for example, W. Beckh 
and G. V. Kulchar Arch. Derm. 
Syphilol. 40, 1–12; 1939), but has 
long since been forgotten.
Dov Stekel University of 
Nottingham, UK.
dov.stekel@nottingham.ac.uk
Mouse avatars guide 
immunotherapy
We think your discussion on 
the use of mice with human 
tumours as cancer models is too 
pessimistic (Nature 560, 156–157; 
2018). These mouse ‘avatars’ 
can now be armed with human 
immune cells and are already 
providing promising insights into 
immunotherapies (Y. Choi et al. 
Exp. Mol. Med. 50, 99; 2018).
One example is a personalized 
mouse model we developed for 
melanoma. Here, the tumour 
and immune cells come from the 
same individual and the response 
of the mouse to immunotherapy 
matches that of the patient 
Keep groundwater 
clear of pesticides 
Pesticide residues from 
Denmark’s intensive-farming 
industry are contaminating the 
country’s groundwater, which 
is used exclusively as its source 
of tap water (see, for example, 
go.nature.com/2iumpdx). This 
is despite the governments’s raft 
of protection measures that have 
been in place since 1994 (see 
go.nature.com/2xhinf7).
Pesticide residues in drinking 
water are a threat to public 
health. They can compromise 
Funding: practices 
risk promoting bias
Funding processes seem to us 
to be rewarding only particular 
types of scientist. This is leading 
to discriminatory practices in the 
very institutions that encourage 
scientists to overcome their 
implicit biases when making 
decisions and assessments.
Drawing examples from 
biomedicine, UK funding 
initiatives are increasingly 
calling for applications from 
investigators who feel they are 
potentially future leaders who 
can make a leap, tackle a grand 
challenge, be transformative and 
advance a unique, game-changing 
strategic vision. Such wording 
risks discouraging more-modest 
scientists and those patiently 
pursuing slowly unfolding 
advances.
Interviews that are designed to 
seek out such ‘winning’ qualities 
could select against those 
scientists who might be unnerved 
by a daunting committee. By 
extension, academic institutions 
must recruit scientists who fit 
these norms if they are to succeed 
in today’s competitive funding 
climate.
Efforts to promote diversity in 
science will fail if the exemplar 
of a successful scientist is so 
narrowly defined. We need 
more-inclusive hallmarks of 
performance, as well as equality 
legislation and training.  
Wendy Bickmore, 
Sarah Cunningham-Burley, 
Margaret Frame University of 
Edinburgh, UK.  
wendy.bickmore@igmm.ed.ac.uk
Funding: gamble on 
radical proposals
The competition to secure 
funding can deter applicants 
from submitting radical 
research proposals, despite their 
potential for dramatic advance. 
At University College London 
(UCL), we have been running 
a programme for ten years that 
bypasses conventional funding 
mechanisms, using our own 
resources to open up new and 
unpredictable lines of enquiry. 
A grant-application system 
such as that used today would 
probably have denied support to 
many of the twentieth-century 
scientists who fundamentally 
changed the ways we think. For 
example, molecular biologist 
Oswald Avery and his colleagues 
disproved the widely held belief 
that the genetic molecule was a 
protein (O. T. Avery et al. J. Exp. 
Med. 79, 137–158; 1944). 
UCL took its lead from British 
Petroleum’s Venture Research 
Unit (1980–93), which awarded 
funding to a handful of applicants 
with radical ideas — simply 
on the basis of face-to-face 
discussion. 
Despite vetoes by peer 
reviewers, the unit supported 
academics such as Ken 
Seddon, who became the 
United Kingdom’s most cited 
chemist for his work on ionic 
liquids, and Steve Davies, who 
set up a company to further 
his research into molecular 
architecture and chiral selection. 
The company sold in 2000 
for £316 million (then about 
US$200 million) — some 
15 times the unit’s total outlay on 
venture research.
Universities should follow 
UCL’s lead and use their own 
resources to set up similar 
initiatives.
Don Braben University College 
London, UK.
don.braben@btinternet.com 
neuroendocrine development in 
unborn and newborn children 
and can lead to chronic kidney 
diseases in later life (X. Xu et al. 
Nature Rev. Nephrol. 14, 313–
324; 2018), as well as to other, 
unforeseeable effects. 
Pesticides therefore need to 
be removed at the waterworks 
before consumption — a 
process that is economically and 
environmentally costly. And it 
is uncertain whether current 
technology can remove all such 
residues (P. J. J. Alvarez et al. 
Nature Nanotech. 13, 634–641; 
2018). 
We call for greater political 
accountability and better 
management of the country’s 
groundwater. In our view, areas 
where groundwater is abstracted 
should be protected against 
pesticide use and farmers should 
receive economic compensation. 
Without such measures, 
Denmark could end up losing 
its role in setting the agenda for 
sustainable use of pesticides 
through European Union 
directives, the United Nations 
Environment Programme and 
the Stockholm Convention on 
Persistent Organic Pollutants.
Christian Sonne, Martin 
Hansen Aarhus University, 
Roskilde, Denmark.
Aage K. Olsen Alstrup Aarhus 
University, Aarhus, Denmark. 
cs@bios.au.dk
(see H. Jespersen et al. Nature 
Commun. 8, 707; 2017). 
Difficulties in getting some 
human grafts to grow successfully 
in mice could hinder the 
widespread application of avatar 
techniques in routine cancer care. 
Melanoma xenografts are unusual 
in that they engraft and grow fast 
enough to support the initiation 
of immunotherapy in patients. 
For ethics reasons, however, 
avatars are better suited to clinical 
research, for example, to screen 
patients’ suitability for trials. 
Jonas A. Nilsson, Roger 
Olofsson Bagge, Lars Ny 
University of Gothenburg, Sweden. 
jonas.a.nilsson@surgery.gu.se
1 9 2  |  N A T U R E  |  V O L  5 6 2  |  1 1  O C T O B E R  2 0 1 8 ©
 
2018
 
Spri nger
 
Nature
 
Li mited.
 
All
 
ri ghts
 
reserved.
